Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06008691 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Study acronym: FIL_MAB
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 3 of 61 sitesv5
  2. Study sites: 58 to 61v4
  3. Site details revised at 19 of 58 sitesv3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 2023 to Dec 27, 2023
    • Site details revised at 58 of 58 sites
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, observational cohort study to evaluate the clinical impact of novel Monoclonal AntiBodies (MAB) in B-cell Non-Hodgkin Lymphoma (NHL) in Italian clinical practice.
Trial Details
NCT Number NCT06008691
Lead Sponsor Fondazione Italiana Linfomi - ETS
Collaborators: Roche Pharma AG
Conditions
(from sponsor)		 Non-Hodgkin Lymphoma, B-cell
Related terms Lymphoma, Non-Hodgkin
Enrollment 1,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov